H Bartelink

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. pmc Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer
    Jolien Heukelom
    Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    BMC Cancer 13:84. 2013
  2. ncbi request reprint Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic?
    Harry Bartelink
    Netherlands Cancer Institute, The Netherlands
    Radiother Oncol 104:139-42. 2012
  3. pmc AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis
    Shuraila F Zerp
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Radiat Oncol 4:47. 2009
  4. pmc Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
    Jos A van der Hage
    Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 13:R68. 2011
  5. pmc Predicting a local recurrence after breast-conserving therapy by gene expression profiling
    Dimitry S A Nuyten
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R62. 2006
  6. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
  7. doi request reprint Hypofractionation in radiotherapy for breast cancer
    Harry Bartelink
    Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands
    Lancet 371:1050-2. 2008
  8. ncbi request reprint Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation
    H Bartelink
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam
    N Engl J Med 345:1378-87. 2001
  9. ncbi request reprint The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 38:216-22. 2002
  10. ncbi request reprint Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial
    H Bartelink
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 38:667-73. 2002

Detail Information

Publications87

  1. pmc Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer
    Jolien Heukelom
    Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    BMC Cancer 13:84. 2013
    ..We will analyze the predictive value of biological markers and (89)Zr-Cetuximab uptake for treatment outcome of chemoradiation with Cetuximab or cisplatin to improve patient selection...
  2. ncbi request reprint Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic?
    Harry Bartelink
    Netherlands Cancer Institute, The Netherlands
    Radiother Oncol 104:139-42. 2012
    ..In an attempt to improve this we give preoperative PBI within a prospective trial...
  3. pmc AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis
    Shuraila F Zerp
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Radiat Oncol 4:47. 2009
    ..Consequently, inhibition of the anti-apoptotic functions of Bcl-2 family members represents a promising strategy to overcome resistance to anticancer therapies...
  4. pmc Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
    Jos A van der Hage
    Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 13:R68. 2011
    ..The purpose of this study was to determine the prognostic value of established clinical and pathological prognostic factors in young breast cancer patients...
  5. pmc Predicting a local recurrence after breast-conserving therapy by gene expression profiling
    Dimitry S A Nuyten
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R62. 2006
    ..Here we have used gene expression profiling by microarray analysis to identify gene expression profiles that can help to predict local recurrence in individual patients...
  6. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  7. doi request reprint Hypofractionation in radiotherapy for breast cancer
    Harry Bartelink
    Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands
    Lancet 371:1050-2. 2008
  8. ncbi request reprint Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation
    H Bartelink
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam
    N Engl J Med 345:1378-87. 2001
    ..We evaluated the effect of a supplementary dose of radiation to the tumor bed on the rates of local recurrence among patients who received radiotherapy after breast-conserving surgery for early breast cancer...
  9. ncbi request reprint The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 38:216-22. 2002
    ..Examples include topoisomerase 1 (topo1) inhibitors, alkyl-lysophospholipids, epidermal growth factor receptor (EGFR) receptor inhibitors...
  10. ncbi request reprint Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial
    H Bartelink
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 38:667-73. 2002
    ..Similar acute and late toxicities were seen in both treatment arms...
  11. ncbi request reprint Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies revisited
    H Bartelink
    Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast 16:S84-8. 2007
    ..Finally new possibilities of sophisticated radiotherapy approaches allow further minimizing the late toxicity of radiotherapy...
  12. ncbi request reprint Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial
    Harry Bartelink
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 25:3259-65. 2007
    ..To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy...
  13. ncbi request reprint Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a standard?
    Harry Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast 12:475-82. 2003
    ..It has now become the standard part of the breast-conserving procedure, as well as in patients who underwent mastectomy with T3+tumor and/or 4 or more positive lymphnodes in axilla...
  14. doi request reprint The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial
    P M Poortmans
    Department of Radiation Oncology, Dr Bernard Verbeeten Institute, PO Box 90120 5000 LA Tilburg, The Netherlands
    Cancer Radiother 12:565-70. 2008
    ..To investigate the impact of the boost dose to the primary tumour bed in the framework of breast conserving therapy on local control, cosmetic results, fibrosis and overall survival for patients with early stage breast cancer...
  15. pmc Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy
    E P M Jansen
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Br J Cancer 97:712-6. 2007
    ..orally. This phase I/II study demonstrated that chemoradiotherapy with daily cisplatin and capecitabine is feasible in postoperative gastric cancer at the defined dose level and is currently being tested in a phase III multicenter study...
  16. ncbi request reprint Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:2040-9. 1997
    ....
  17. ncbi request reprint Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
    E P Jansen
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 48:27-35. 2000
    ..As most patients present with locally advanced disease, the possibility of radical surgery is limited. Consequently, radiotherapy is often needed as monotherapy or as an adjunct to surgery...
  18. ncbi request reprint Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients
    R L M Haas
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 41:1724-30. 2005
    ..It appears that LD-IF-RT is a valuable asset in the management of relapsed disease in both indolent and aggressive lymphoma and should be considered to palliate symptoms in patients with recurrent and/or chemotherapy refractory disease...
  19. pmc Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
    F J P Hoebers
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 61:1075-81. 2008
    ..In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated...
  20. ncbi request reprint Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group
    G van Tienhoven
    University of Amsterdam, Department of Radiotherapy, The Netherlands
    Eur J Cancer 35:32-8. 1999
    ....
  21. doi request reprint Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial
    Philip M Poortmans
    Department of Radiation Oncology, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
    Radiother Oncol 90:80-5. 2009
    ..To assess the impact of the boost dose in patients with involved surgical margins...
  22. ncbi request reprint Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
    C Vrieling
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 39:932-44. 2003
    ....
  23. ncbi request reprint Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials
    A C Voogd
    Eindhoven Cancer Registry, The Netherlands Cancer Institute, Eindhoven, The Netherlands
    J Clin Oncol 19:1688-97. 2001
    ..Risk factors for local and distant recurrence after breast-conserving therapy and mastectomy were compared to define guidelines for the decision making between both treatments...
  24. ncbi request reprint Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer
    A L Uitterhoeve
    Academic Medical Center, University of Amsterdam, Department of Radiation Oncology, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
    Eur J Cancer 36:592-600. 2000
    ..This treatment schedule is at present being tested as one of the two treatment arms of EORTC phase III study protocol 08972/22973...
  25. ncbi request reprint Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882
    Ninja Antonini
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Radiother Oncol 82:265-71. 2007
    ..To determine whether the effect of an additional "boost" radiation after breast conservative therapy (BCT) on local control depends on age and evaluate the impact of a treatment policy with a threshold for age...
  26. ncbi request reprint Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder
    L Moonen
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoeck Huis, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 49:1305-10. 2001
    ....
  27. ncbi request reprint Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial
    H Bartelink
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:207-15. 1997
    ....
  28. ncbi request reprint Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis
    G A Ruiter
    Department of Radiotherapy, Antoni van Leeuwenhoek Ziekenhuis The Netherlands Cancer Institute, Amsterdam
    Cancer Res 59:2457-63. 1999
    ..This type of modulation of specific signal transduction pathways in tumor cells may lead to the development of new therapeutic strategies...
  29. doi request reprint The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment
    Shafak Al Uwini
    Department of Radiotherapy, Erasmus Medical Centre, Rotterdam, The Netherlands
    Radiother Oncol 93:87-93. 2009
    ..The purpose of this study was to investigate the effect of CT-based delineation and planning on the irradiated boost volume. For this specific purpose we used the data as derived from 2 prospective phase III randomised trials...
  30. ncbi request reprint From translational research to improved local control and survival: the Gilbert Fletcher Award Lecture, Lugano, March 2000
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antonio van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 49:311-8. 2001
    ..In analogy to the results obtained with concomitant radiotherapy and chemotherapy, this will lead to improved local control and survival rates in cancer patients...
  31. ncbi request reprint In vitro differentiation characteristics of human skin fibroblasts: correlations with radiotherapy-induced breast fibrosis in patients
    N S Russell
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoekhuis, Amsterdam
    Int J Radiat Biol 76:231-40. 2000
    ..To determine whether there is an association between dermal fibroblast differentiation characteristics in vitro and breast fibrosis developing in patients following radiotherapy for breast cancer...
  32. ncbi request reprint [The concomitant use of radiotherapy and chemotherapy for the treatment of solid malignant tumors]
    H Bartelink
    Afd Radiotherapie, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 146:504-8. 2002
    ..Major further improvement can be expected from the design and use of new drugs that influence the pathways leading to cell death after irradiation...
  33. ncbi request reprint Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial
    J M Immink
    Department of Radiotherapy, Medical Center, Reinier de Graaf Groep, Delft, The Netherlands
    Ann Oncol 23:2591-8. 2012
    ..In breast cancer treated with breast-conserving radiotherapy, the influence of the boost dose on cosmetic outcome after long-term follow-up is unknown...
  34. doi request reprint Progress in radiotherapy for early breast cancer
    H Bartelink
    Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
    Ann Oncol 19:v117-21. 2008
  35. ncbi request reprint Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer
    O E Nieweg
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:179-81. 2004
    ....
  36. ncbi request reprint Potential of radiation-induced chromosome aberrations to predict radiosensitivity in human tumour cells
    J M Coco Martin
    Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam
    Int J Radiat Biol 75:1161-8. 1999
    ..If so, this would potentially provide a more rapid method than the colony assay to predict radiocurability in human tumour biopsy material...
  37. ncbi request reprint Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)
    Frank J P Hoebers
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Cancer 119:750-6. 2006
    ..However, systemic adduct levels (WBC and buccal cells) from IV patients were higher than in IA patients, consistent with less systemic exposure after IA administration...
  38. ncbi request reprint Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment?
    Floris Pos
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 61:678-86. 2005
    ..To evaluate our long-term results of bladder preservation with brachytherapy in the treatment of bladder cancer...
  39. ncbi request reprint A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer
    Edwin P M Jansen
    Department of Radiotherapy of The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 69:1424-8. 2007
    ..Therefore, this Phase I-II dose-escalation study was performed to determine the maximal tolerated dose and toxicity profile of postoperative radiotherapy combined with concurrent capecitabine...
  40. ncbi request reprint Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer
    Edwin P M Jansen
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 67:781-5. 2007
    ..Because renal toxicity is one of the most serious late complications in upper abdominal radiotherapy, we prospectively analyzed kidney function in patients who underwent postoperative chemoradiotherapy for gastric cancer...
  41. ncbi request reprint Sophisticated radiotherapy with optimal surgery is the way forward
    Nicola S Russell
    Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Curr Opin Oncol 16:529-35. 2004
    ..This review assesses the most recent evidence generated by clinical scientists in the field of radiotherapy for breast cancer...
  42. ncbi request reprint The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial
    Philip Poortmans
    Department of Radiotherapy, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
    Radiother Oncol 72:25-33. 2004
    ..This paper investigates the potential impact of the different boost techniques on local control and on fibrosis after breast conserving therapy...
  43. ncbi request reprint In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients
    Rick L M Haas
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 59:782-7. 2004
    ..To evaluate (99m)Tc-Annexin-V (TAV) scintigraphy in monitoring radiation-induced apoptotic cell death in follicular lymphoma (FL) patients...
  44. ncbi request reprint Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer
    Floris J Pos
    Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 59:696-705. 2004
    ....
  45. ncbi request reprint Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
    Jose Belderbos
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Eur J Cancer 43:114-21. 2007
    ..A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients...
  46. ncbi request reprint Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast
    Philip Meijnen
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Ann Surg Oncol 15:235-43. 2008
    ..The effect of treatment of patients diagnosed with ductal carcinoma in situ (DCIS) of the breast was evaluated, and factors associated with local recurrence were assessed...
  47. ncbi request reprint Reproducibility of the assessment of tumor extent in the breast using multiple image modalities
    William F A Klein Zeggelink
    Department of Radiology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Med Phys 30:2919-26. 2003
    ....
  48. doi request reprint Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy
    Joep Stroom
    Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 74:898-905. 2009
    ..This study aimed to quantify the incidence and extension of microscopic disease around primary breast tumors in patients undergoing breast-conserving therapy (BCT), focusing on a potential application to reduce radiotherapy boost volumes...
  49. ncbi request reprint Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and
    Nina Bijker
    Department of Radiation Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 24:3381-7. 2006
    ..We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors...
  50. ncbi request reprint High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas
    R L M Haas
    Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 21:2474-80. 2003
    ..To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma...
  51. ncbi request reprint [Total mesorectal excision and preoperative radiotherapy in patients with rectal carcinoma: good preliminary results]
    H Bartelink
    Het Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis, afd. Radiotherapie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 145:2259-60. 2001
    ..Long term results should give greater insight into potential improvements in survival rates and any late side effects which may arise as a result of the radiation schedule...
  52. ncbi request reprint Long-term risk of cardiovascular disease in 10-year survivors of breast cancer
    Maartje J Hooning
    Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Natl Cancer Inst 99:365-75. 2007
    ..Few data on long-term cardiovascular disease risk according to specific radiation fields are available, and interaction with known cardiovascular risk factors has not been examined...
  53. ncbi request reprint Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy
    Bas Kreike
    Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Clin Cancer Res 12:5705-12. 2006
    ..We used cDNA microarray analysis to identify gene expression profiles associated with local recurrence...
  54. ncbi request reprint A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...
  55. ncbi request reprint Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients
    Eline E Deurloo
    Department of Radiology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur Radiol 16:692-701. 2006
    ..Subgroups of patients in whom MRI has complementary value may be defined by the differences in clinical and imaging features...
  56. ncbi request reprint Intraoperative radiotherapy for breast cancer: tail wagging the dog?
    Harry Bartelink
    Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands
    Lancet Oncol 5:207-8. 2004
  57. doi request reprint Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 15:4181-90. 2009
    ..Several clinical risk factors are associated with local recurrence (LR) after BCT but are unable to explain all instances of LR after BCT. Here, gene expression microarrays are used to identify novel risk factors for LR after BCT...
  58. doi request reprint Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer
    E Tanis
    Department of Surgery, The Netherlands Cancer Institute, The Netherlands
    Eur J Cancer 48:1751-6. 2012
    ..Controversy exists concerning the prognostic impact of a LRR after a very long event-free interval...
  59. doi request reprint The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study
    K E Pengel
    Department of Radiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital NKI AVL, Amsterdam, The Netherlands
    Breast Cancer Res Treat 116:161-9. 2009
    ..To assess whether preoperative contrast-enhanced magnetic resonance imaging (MRI) of the breast influences the rate of incomplete tumor excision...
  60. doi request reprint Multiinstitutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines
    Anke M van Mourik
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Radiother Oncol 94:286-91. 2010
    ..This study aims to determine magnitude, causes and consequences of post-operative breast tumour target volume delineation variation among radiation oncologists in the presence of guidelines...
  61. ncbi request reprint Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53
    F Ong
    Department of Radiotherapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX The, Amsterdam, Netherlands
    Radiother Oncol 61:169-75. 2001
    ..This relationship was found for local control and disease-free, disease-specific and overall survival...
  62. ncbi request reprint Radiation-induced apoptosis
    M Verheij
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
    Cell Tissue Res 301:133-42. 2000
    ..This review discusses mechanisms of radiation-induced apoptosis and highlights the radiobiological and radiotherapeutical relevance of this mode of cell death...
  63. ncbi request reprint Radiation-induced apoptosis--the ceramide-SAPK signaling pathway and clinical aspects
    M Verheij
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam
    Acta Oncol 37:575-81. 1998
    ..Finally, data are presented to illustrate the potential clinical relevance of apoptosis...
  64. ncbi request reprint Clinical results of image-guided deep inspiration breath hold breast irradiation
    Gerben R Borst
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 78:1345-51. 2010
    ....
  65. ncbi request reprint Expedition Inspiration Fund for Breast Cancer Research Meeting 2003
    Harry Bartelink
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 80:139-44. 2003
  66. ncbi request reprint The effect of set-up uncertainties, contour changes, and tissue inhomogeneities on target dose-volume histograms
    B C John Cho
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Department of Radiotherapy, Amsterdam
    Med Phys 29:2305-18. 2002
    ..Interpolation is a valid, efficient method to approximate DVHs...
  67. ncbi request reprint Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 71:1014-21. 2008
    ..5 years. In the present study, we evaluated the IBR incidence and the risk factors for IBR after prolonged follow-up...
  68. ncbi request reprint Simplified intensity-modulated radiotherapy using pre-defined segments to reduce cardiac complications in left-sided breast cancer
    B C John Cho
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Radiother Oncol 70:231-41. 2004
    ....
  69. ncbi request reprint Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years
    Lucille D A Dorresteijn
    Department of Neuro Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoekhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 20:282-8. 2002
    ..To estimate the risk of ischemic stroke in patients irradiated for head and neck tumors...
  70. ncbi request reprint Long-term cause-specific mortality of patients treated for Hodgkin's disease
    Berthe M P Aleman
    Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 21:3431-9. 2003
    ..To assess long-term cause-specific mortality of young Hodgkin's disease (HD) patients...
  71. ncbi request reprint Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients
    Rick L M Haas
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
    Radiother Oncol 69:323-8. 2003
    ..To study thallium-201-chloride scintigraphy (201Tl-S) in staging and monitoring response after radiotherapy in follicular lymphoma (FL) patients...
  72. ncbi request reprint Determining optimal two-beam axial orientations for heart sparing in left-sided breast cancer patients
    B C John Cho
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Department of Radiotherapy, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Med Phys 31:111-21. 2004
    ..e., conformal versus intensity modulation) on the optimal objective cost function...
  73. doi request reprint Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
    Breast Cancer Res Treat 122:711-20. 2010
    ....
  74. ncbi request reprint Late cardiotoxicity after treatment for Hodgkin lymphoma
    Berthe M P Aleman
    Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Blood 109:1878-86. 2007
    ..Anthracyclines further increase the elevated risks of CHF and valvular disorders from mediastinal radiotherapy...
  75. ncbi request reprint Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway
    Gerald A Ruiter
    Department of Radiotherapy, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Anticancer Drugs 14:167-73. 2003
    ..Inhibition of the PI3K-Akt/PKB survival pathway represents a novel mode of action of ALPs that may significantly contribute to the induction of apoptosis...
  76. ncbi request reprint Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours
    Stefan R Vink
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, The Netherlands
    Radiother Oncol 80:207-13. 2006
    ..The purpose of this phase I study was to determine the feasibility and tolerability of concurrent daily perifosine and radiation in patients with advanced cancer...
  77. ncbi request reprint Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period
    Philip M P Poortmans
    Department of Radiotherapy, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
    Radiother Oncol 76:278-84. 2005
    ..To evaluate the impact of quality assurance on treatment compliance, we compared the outcome of the two individual case reviews (ICR) conducted early and late during the accrual period of a large prospective multi-centre trial...
  78. doi request reprint Prognostic and predictive markers in oncology. Introduction
    Harry Bartelink
    Semin Radiat Oncol 18:73-4. 2008
  79. ncbi request reprint Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
    Hans Wildiers
    Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:1101-15. 2007
    ..The available evidence was reviewed and synthesised to provide consensus recommendations regarding the care of breast cancer in older adults...
  80. ncbi request reprint Re: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see?
    Berthe M P Aleman
    J Natl Cancer Inst 96:235-6; author reply 236-7. 2004
  81. ncbi request reprint Multifocal ductal carcinoma in situ of the breast: a contraindication for breast-conserving treatment?
    Philip Meijnen
    J Clin Oncol 25:5548-9. 2007
  82. ncbi request reprint Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast
    Lawrence J Solin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer 103:1137-46. 2005
    ..The objective of the current study was to determine the long-term outcome after breast-conservation surgery followed by definitive breast irradiation for women with mammographically detected DCIS of the breast...
  83. ncbi request reprint Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes
    Elena Musat
    EORTC, Avenue E Mounierlaan, 83 11, 1200 Brussels, Belgium
    Eur J Cancer 43:718-24. 2007
    ..In the final trial analysis, a sensitivity analysis should evaluate the subgroup of patients receiving an optimal treatment to verify the robustness of the results and the true impact of IM-MS irradiation...
  84. ncbi request reprint Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ
    Lawrence J Solin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Eur J Cancer 41:1715-23. 2005
    ..Close follow-up after initial breast conservation treatment with radiation is warranted for the early detection of potentially salvageable local and local-regional recurrences...
  85. ncbi request reprint Increased carotid wall thickening after radiotherapy on the neck
    Lucille D A Dorresteijn
    Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 41:1026-30. 2005
    ..Screening and treatment of additional cerebrovascular risk factors which contribute to further IMT thickening and stroke development is recommended, especially in radiotherapy patients with a favourable prognosis...
  86. pmc Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
    Howard Y Chang
    Program in Epithelial Biology, Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 102:3738-43. 2005
    ....
  87. ncbi request reprint Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents
    Shuraila F Zerp
    Division of Cellular Biochemistry, Department of Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan, CX Amsterdam, The Netherlands
    Anticancer Drugs 19:65-75. 2008
    ..Interference with the angiogenic process represents a novel mode of action of APLs and might significantly contribute to the antitumor effect of these compounds...